926233-78-5

Basic information

• Product Name: N-(3-aminophenyl)-2-(trifluoromethyl)benzamide
• Synonyms: N-(3-aminophenyl)-2-(trifluoromethyl)benzamide
• CAS NO: 926233-78-5
• Molecular Formula: C₁₄H₁₁F₃N₂O
• Molecular Weight: 280.2451496
• Mol File: 926233-78-5.mol

Chemical Properties

• Boiling Point: 331.552°C at 760 mmHg
• Flash Point: 154.317°C
• Appearance: /
• Density: 1.373g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.602
• CAS DataBase Reference: N-(3-aminophenyl)-2-(trifluoromethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-aminophenyl)-2-(trifluoromethyl)benzamide(926233-78-5)
• EPA Substance Registry System: N-(3-aminophenyl)-2-(trifluoromethyl)benzamide(926233-78-5)

Safety Data

• Hazardous Substances Data: 926233-78-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H11F3N2O/c15-14(16,17)12-7-2-1-6-11(12)13(20)19-10-5-3-4-9(18)8-10/h1-8H,18H2,(H,19,20)

Upstream product

• 425616-34-8 N-(3-nitrophenyl)-2-trifluoromethylbenzamide 
• 99-09-2 3-nitro-aniline 
• 312-94-7 2-trifluoromethylbenzoyl chloride 

Downstream Products

• 1622869-09-3 C₂₁H₁₅F₃N₂O₂ 

Relevant articles and documents

Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold

TASK-1 is a two-pore domain potassium channel that is important to modulating cell excitability, most notably in the context of neuronal pathways. In order to leverage TASK-1 for therapeutic benefit, its physiological role needs better characterization; however, designing selective inhibitors that avoid the closely related TASK-3 channel has been challenging. In this study, a series of bis-amide derived compounds were found to demonstrate improved TASK-1 selectivity over TASK-3 compared to reported inhibitors. Optimization of a marginally selective hit led to analog 35 which displays a TASK-1 IC 50 = 16 nM with 62-fold selectivity over TASK-3 in an orthogonal electrophysiology assay.

Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor

Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide (18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 ± 0.05 μM, COX-2 IC50 = 210 ± 10 μM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.